You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Drug Price Trends for NDC 00456-1203


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 00456-1203

Drug Name NDC Price/Unit ($) Unit Date
LINZESS 72 MCG CAPSULE 00456-1203-30 18.13706 EACH 2025-11-19
LINZESS 72 MCG CAPSULE 00456-1203-30 18.13635 EACH 2025-10-22
LINZESS 72 MCG CAPSULE 00456-1203-30 18.13019 EACH 2025-09-17
LINZESS 72 MCG CAPSULE 00456-1203-30 18.12813 EACH 2025-08-20
LINZESS 72 MCG CAPSULE 00456-1203-30 18.13001 EACH 2025-07-23
LINZESS 72 MCG CAPSULE 00456-1203-30 18.12205 EACH 2025-06-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 00456-1203

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00456-1203

Last updated: July 28, 2025

Introduction

The drug identified by NDC 00456-1203 is a critical pharmaceutical product within its therapeutic class, exhibiting substantial clinical relevance and commercial potential. This report provides a comprehensive market analysis and price projection strategy, aimed at guiding stakeholders through current dynamics, growth drivers, competitive landscape, and future pricing trajectories.

Product Overview

NDC 00456-1203 corresponds to [Insert Exact Drug Name] (hereafter referred to as "the drug"). It is indicated for [primary indication, e.g., autoimmune disorders, oncology, etc.]. The formulation, dosage, and administration route are consistent with [standard pharmaceutical practices or specifics], positioning it within [therapeutic class]. The drug's approval status, patent expiry date, and existing manufacturing capacity underpin its current market standing.

Market Landscape

Therapeutic Area and Market Size

The drug operates within the [therapeutic class, e.g., immunotherapy, cancer treatment, etc.], a sector projected to reach $X billion globally by 20XX, with a Compound Annual Growth Rate (CAGR) of X% (from [source]). Key drivers include increasing disease prevalence, advancements in targeted therapies, and unmet medical needs.

Target Patient Population

Current estimates suggest [specific number or percentage] of the population are eligible for this treatment, with a significant portion concentrated in [geographies such as North America, Europe, emerging markets]. The expanding diagnostic capabilities and broader indications contribute to sustained growth.

Regulatory Environment

Regulatory trends favor accelerated approval pathways, particularly for rare diseases or unmet needs, potentially shortening time-to-market for future generics or biosimilars. Patent expiry, typically in [year], indicates imminent generic entry, influencing pricing strategies and market share.

Competitive Landscape

Major competitors comprise [list top competitors, e.g., branded drugs, biosimilars, generics]. The landscape is characterized by:

  • Patent protections until [year],
  • Pending biosimilar entries,
  • Ongoing clinical trials for alternative formulations or combination therapies.

Market Penetration and Adoption

Adoption rates are driven by [clinical efficacy, safety profile, reimbursement) factors]. Payer policies, insurance coverage, and physician prescribing patterns significantly influence market penetration.

Pricing Dynamics

Current Pricing

The average wholesale price (AWP) for the branded product is approximately $X per dose/package (source: [pricing database]). Reimbursement levels vary based on geography, patient assistance programs, and negotiated discounts.

Pricing Drivers

Factors influencing current and future prices include:

  • Patent status and exclusivity periods,
  • Competition from biosimilars or generics,
  • Manufacturing costs,
  • Regulatory approvals and labeling,
  • Market access strategies and negotiated discounts.

Forecasting Price Trends

Short-term (1-3 years)

In the immediate future, the drug’s price is expected to [remain stable/decline slightly/face downward pressure], largely due to impending biosimilar entries scheduled around [year]. The expiration of patent rights typically induces price erosion, with projected reductions of X-XX% (source: [industry analysis]).

Medium-term (4-7 years)

The entry of biosimilars may lead to [further price decreases or stabilization]. However, innovative formulation or label expansions could mitigate pricing erosion, maintaining premium pricing levels for the originator.

Long-term (8+ years)

Post-patent expiry, the drug could see price convergence with biosimilars or generics, potentially lowering costs by up to 50-70% (based on historical precedents). Patent litigation and market exclusivity extensions may temporarily delay this trend.

Market Growth and Revenue Projections

Revenue forecasts depend on:

  • Market penetration rates,
  • Price erosion dynamics,
  • Regulatory and reimbursement landscape,
  • Competitive actions.

Based on current estimates, [Company Name] could realize a revenue of $X billion in the next [Y] years, assuming [market share] and consistent pricing strategies.

Potential Risks

  • Regulatory delays,
  • Price controls and reimbursement cuts,
  • Emergence of superior therapies,
  • Patent litigations or biosimilar protests.

Strategic Recommendations

To enhance profitability and market positioning, stakeholders should:

  • Invest in lifecycle management,
  • Prepare for biosimilar competition through patent extensions,
  • Explore combination therapies,
  • Engage proactively with payers and healthcare providers.

Conclusions

NDC 00456-1203 situates within a dynamic, high-growth therapeutic segment. Short-term price stability is challenged by biosimilar entry, but strategic innovation and lifecycle extensions can sustain revenue streams. Long-term, market fundamentals suggest significant price reductions, aligning with biosimilar proliferation.


Key Takeaways

  • The drug operates in a rapidly expanding, competitive market vulnerable to biosimilar competition post-patent expiry.
  • Current price points are primarily dictated by patent protections, with projected declines contingent on biosimilar uptake.
  • Near-term revenues depend on market penetration and pricing strategies; long-term outlook inclines toward substantial price erosion.
  • Strategic patent and lifecycle management are critical to maintaining profitability amid increasing competition.
  • Stakeholders should monitor regulatory trends, competitors’ actions, and reimbursement policies to adapt dynamically.

FAQs

1. When is the patent expiry for NDC 00456-1203, and what implications does this have?
Patent expiry is scheduled for [year], opening the market to biosimilar competitors, which are likely to cause significant price reductions and market share shifts.

2. How will biosimilar entry affect the drug’s pricing and market share?
Biosimilar entry typically leads to a price decrease of 50-70% and diminishes the market share of the originator unless the brand adopts aggressive lifecycle management or offers differentiated value.

3. What are the key drivers of growth for this drug in the next five years?
Key drivers include expanded indication approvals, increased diagnosis rates, reimbursement support, and successful market penetration strategies.

4. How does regulatory policy influence pricing projections?
Regulatory agencies’ stance on biosimilar approval, price controls, and reimbursement policies directly influence market entry, pricing strategies, and overall revenue potential.

5. Are there upcoming clinical trials or label expansions that could alter the market landscape?
Ongoing trials for [specific indications or combinations] may extend the product’s exclusivity and bolster its positioning, potentially stabilizing prices and affirming its market dominance.


Sources

  1. [1] MarketResearch.com. Global Immunotherapy Market Report, 20XX.
  2. [2] FDA Label Database, 20XX.
  3. [3] IQVIA. Drug Pricing and Market Trends, 20XX.
  4. [4] Biosimilar Market Insights, 20XX.
  5. [5] Company Financial Reports and Patent Filings, 20XX.

Note: Specific details such as drug name, indication, patent expiry, and pricing figures require access to proprietary or publicly available detailed data sources for complete precision.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.